[Comparison of the efficacy and safety of Bortezomib between the twice-weekly and once-weekly regimens for newly diagnosed multiple myeloma].

Abstract

Sorry, we couldn't extract an abstract for this paper.
DOI: 10.3760/cma.j.issn.0253-2727.2017.08.016

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.